Cytosorbents (CTSO) AI Stock Analysis

• Market Cap: $56.35M
• Dividend Yield: N/A
• Average Volume (3M): 124.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: -5.86%
• EPS Growth: 50.76%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 62,610,374
• 10 Day Avg. Volume: 94,932
• 30 Day Avg. Volume: 124,965
• PEG Ratio: 0.41
• Price to Book (P/B): 4.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.61
• Enterprise Value/Market Cap: 1.39
• Enterprise Value/Revenue: 0.54
• Enterprise Value/Gross Profit: 2.90
• Enterprise Value/Ebitda: -0.89
• 1Y Price Target: $1.00
• Price Target Upside: 11.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Cytosorbents faces significant financial challenges, including declining revenues, high leverage, and negative cash flows, necessitating strategic improvements. Technical analysis confirms bearish momentum, while valuation metrics highlight ongoing losses. However, positive developments in earnings guidance and corporate events provide some optimism for future stabilization and growth.

Positive Factors

Financial Management

Management has announced plans to continue to reduce cash burn, which could help extend the cash runway.

Market Expansion

Management plans to revamp associated rep accounts and territories in Germany to lead to deeper penetration, greater adoption, and drive strong growth.

Regulatory Opportunities

The regulatory approval of DrugSorb-ATR in the U.S. and Canada could make it the first device indicated for the removal of antithrombotic agents during cardiac surgery in these markets.

Negative Factors

Earnings Performance

The company reported revenues and net loss that were below consensus estimates, with $9.2M in product revenues and a net loss of $0.14 per share.

Regulatory Challenges

The company received a denial letter from the FDA regarding the 510(k) de novo application for the use of DrugSorb-ATR during coronary artery bypass grafting (CABG) surgery.

Revenue Decline

Product revenues fell by approximately 3% year-over-year and 5% quarter-over-quarter, primarily due to falling direct sales in Germany, the company’s most important market.

Cytosorbents Business Overview & Revenue Model

Company Description

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Cytosorbents generates revenue primarily through the sale of its CytoSorb device, which is marketed and sold to hospitals and healthcare facilities worldwide. The company also engages in strategic partnerships and collaborations with other healthcare organizations to expand the adoption of its technology. Key revenue streams include direct sales of CytoSorb, licensing agreements, and government or institutional grants for research and development. Additionally, the company may earn income from clinical trial support and related consultancy services.

Cytosorbents Financial Statement Overview

Summary

Cytosorbents faces significant financial challenges, including declining revenues, negative net profit margins, high leverage, and negative cash flows. These factors highlight a need for strategic improvements to stabilize financial health.

Income Statement

Cytosorbents has experienced a declining revenue trend, with a significant revenue drop from 2023 to 2024. Gross profit margin remains positive, indicating effective cost management, but negative net profit margin highlights continued operational challenges. The company consistently reports negative EBIT and EBITDA margins, reflecting difficulties in covering operational costs.

Balance Sheet

The company's balance sheet shows a weak position with a high debt-to-equity ratio, indicating significant leverage. The declining stockholders' equity and negative ROE suggest inefficiencies in generating profit from shareholders' investments. The equity ratio reflects a low level of assets funded by equity, highlighting financial vulnerability.

Cash Flow

Cytosorbents' cash flow analysis shows negative operating cash flows, indicating challenges in generating cash from operations. The free cash flow remains negative, reflecting issues in covering capital expenditures. Despite positive financing cash flow, reliance on external financing could pose future liquidity risks.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.59M	36.35M	29.36M	40.11M	39.45M
	Gross Profit
25.13M	22.39M	15.40M	29.06M	28.40M
	EBIT
-16.79M	-31.21M	-31.52M	-22.75M	-10.37M
	EBITDA
-19.26M	-29.18M	-30.00M	-22.01M	-9.71M
	Net Income Common Stockholders
-20.72M	-28.51M	-32.81M	-24.56M	-7.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.28M	14.13M	22.14M	52.14M	71.42M
	Total Assets
47.37M	53.26M	63.23M	89.52M	89.95M
	Total Debt
26.89M	18.31M	18.25M	13.82M	1.03M
	Net Debt
23.61M	4.18M	-3.89M	-38.32M	-70.39M
	Total Liabilities
36.26M	29.99M	27.86M	26.94M	10.73M
	Stockholders Equity
11.11M	23.28M	35.38M	62.58M	79.22M
Cash Flow		Free Cash Flow
-14.71M	-22.59M	-34.69M	-18.29M	-7.29M
	Operating Cash Flow
-14.43M	-21.66M	-28.23M	-14.01M	-5.61M
	Investing Cash Flow
-669.43K	-936.24K	-6.46M	-4.28M	-1.68M
	Financing Cash Flow
9.33M	14.47M	4.96M	715.20K	66.35M

Cytosorbents Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.00, and below the 200-day MA of 1.04, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.78 is Neutral, neither overbought nor oversold. The STOCH value of 35.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTSO.

Cytosorbents Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	67 Neutral	$81.50M	10.56	5.00%	―	0.29%	-22.13%
SRTS	60 Neutral	$73.34M	40.58	3.46%	―	24.75%	-61.29%
XTNT	54 Neutral	$92.29M	―	-26.20%	―	20.81%	-498.66%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
NSPR	47 Neutral	$72.30M	―	-113.95%	―	8.49%	6.09%
HYPR	46 Neutral	$48.36M	―	-67.86%	―	0.34%	6.20%
CTSO	39 Underperform	$56.35M	―	-94.65%	―	-5.86%	50.76%

Cytosorbents Corporate Events

CytoSorbents Appoints New VP and Corporate Controller

On April 17, 2025, CytoSorbents Corporation announced the appointment of Melanie Grossman as Vice President and Corporate Controller, effective April 14, 2025. Grossman, who brings over 25 years of finance and accounting experience, will receive stock awards as an inducement grant under Nasdaq Rule 5635(c)(4). Her expertise is expected to support CytoSorbents’ growth and the potential launch of DrugSorb™-ATR in North America, enhancing the company’s operational efficiency and market positioning.

Spark’s Take on CTSO Stock

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

Cytosorbents’ stock faces significant financial challenges, including declining revenues, high leverage, and negative cash flows, necessitating strategic improvements. While recent earnings and corporate events show positive trends in revenue growth and liquidity, these are offset by technical and valuation concerns, leading to a cautious overall score.

To see Spark’s full report on CTSO stock, click here.

Cytosorbents Appoints New VP of Marketing

On April 14, 2025, CytoSorbents Corporation announced the appointment of Thomas Shannon as Vice President of Marketing for North America. Shannon, with over 25 years of experience in commercializing cardiovascular and critical care technologies, will lead the marketing strategy for DrugSorb™-ATR in the U.S. and Canada. This appointment comes as the company prepares for the potential launch of DrugSorb-ATR, a device aimed at reducing perioperative bleeding in patients undergoing coronary artery bypass graft surgery while on blood thinners. The device is currently under review by the U.S. FDA and Health Canada, with regulatory decisions expected in 2025.

Spark’s Take on CTSO Stock

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

Cytosorbents’ stock faces significant financial challenges, including declining revenues, high leverage, and negative cash flows, necessitating strategic improvements. While recent earnings and corporate events show positive trends in revenue growth and liquidity, these are offset by technical and valuation concerns, leading to a cautious overall score.

To see Spark’s full report on CTSO stock, click here.

CytoSorbents Reschedules Earnings Release to March 2025

CytoSorbents Corporation announced the rescheduling of its fourth quarter and full year 2024 earnings release to March 31, 2025, to allow additional time for the completion of its annual audit. The company reaffirmed its preliminary financial results, expecting significant growth in product revenue and gross margin compared to the previous year. The company’s marketing applications for DrugSorb-ATR are under review by the U.S. FDA and Health Canada, with decisions anticipated in 2025. Additionally, CytoSorbents raised $7.85 million in the first quarter of 2025, enhancing its cash position as it continues to develop its innovative blood purification technologies.

CytoSorbents Delays Earnings Release to March 25, 2025

CytoSorbents Corporation announced the postponement of its earnings release, originally scheduled for March 6, 2025, to March 25, 2025, following the passing of its Vice President and Corporate Controller, James E. Cason, Jr. The company reaffirmed its preliminary financial results for 2024, expecting significant growth in product revenue and gross margins. The delay aims to ensure a thorough completion of the annual audit. CytoSorbents also continues to anticipate regulatory decisions on its DrugSorb™-ATR marketing applications in 2025, which are under review by the U.S. FDA and Health Canada.

CytoSorbents Boosts Liquidity with Warrant Expiration

On February 25, 2025, CytoSorbents Corporation announced the expiration of its Series A Right Warrants, resulting in $1.6 million in gross proceeds from their exercise. This event, combined with previous fundraising efforts, has strengthened the company’s balance sheet by increasing net liquidity to approximately $12.3 million. The proceeds are intended to support innovation and expansion in CytoSorbents’ core international business and aid in the potential U.S. and Canadian approval of their DrugSorb™-ATR product in 2025. The company also highlighted the ongoing progress of their regulatory applications with the U.S. FDA and Health Canada, expecting decisions in 2025.